24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
30 citations
,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
AMPLEX PLUS may reduce hair loss and promote new hair growth.
January 2021 in “Journal of clinical & experimental dermatology research” LustrivaTM improves hair thickness and reduces facial wrinkles safely.
14 citations
,
August 2021 in “Journal of Pharmaceutical Sciences” Cholesterol- and phospholipid-free niosomes improve deep skin drug delivery.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
June 2021 in “Current developments in nutrition” The LustrivaTM BH-002 supplement and hair serum improved women's hair, skin, and nail health and appearance.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
July 2025 in “Veterinary Parasitology Regional Studies and Reports” NexGard® and Frontline Combo® are both 100% effective at eliminating lice in dogs.
June 2020 in “Journal of clinical and investigative dermatology” Nourkrin® Woman with Marilex® improves hair growth, appearance, and confidence in women with hair loss.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
July 2025 in “International Journal of Pharmaceutical Research and Development” Vitex negundo oil promotes hair growth and may treat hair loss safely.
September 2023 in “Journal of the American Academy of Dermatology” Low-dose oral naltrexone may help reduce inflammation in some scarring alopecia patients.
13 citations
,
January 2017 in “Plastic and reconstructive surgery. Global open” Juvéderm Ultra Plus is safe and effective for treating severe nasolabial folds in Chinese subjects.
January 2025 in “International Journal of Pharmaceutical Research and Development” Vitex negundo oil promotes hair growth and may treat alopecia safely.
November 2016 in “The Molecular Biology Society of Japan” February 2023 in “PLOS ONE” Caizhixuan hair tonic helps treat hair loss by promoting hair growth and improving hair follicles.
5 citations
,
September 2016 in “Journal of Cosmetic Dermatology” Nourkrin® with Marilex® may increase hair count by 35.7% in postpartum hair loss.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
47 citations
,
July 2014 in “European Journal of Pharmaceutics and Biopharmaceutics” Scientists created a gel with nanoparticles to deliver medicine to hair follicles effectively.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
March 2026 in “Journal of Translational Autoimmunity” Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.